Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND-AF
NCT06871228Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib) and atrial flutter (AFL) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoints: Composite of all-cause death, ischemic stroke, or systemic embolism at 48 months and ISTH major bleeding or ISTH clinically relevant non-major bleeding at 48 months. Started Aug 2025; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT06871228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871228.